Julho 2022: De acordo com a pesquisa mais recente conduzida pela Emergen Research, o mercado global de terapia com células T CAR atingiu um tamanho de US$ 1.29 bilhão em 2021 e deverá registrar uma receita CAGR de 24.9% ao longo do período de previsão. Espera-se que a crescente incidência de câncer em todo o mundo, bem como a crescente taxa de mortalidade causada pelo câncer sejam os principais impulsionadores do crescimento da receita no mercado global de terapia celular CAR-T ao longo do período de previsão. A expansão das atividades de ensaios clínicos a um ritmo vertiginoso, a proliferação de fusões e aquisições e o fascínio das ofertas públicas iniciais são fatores que estão contribuindo para o crescimento da receita no mercado global de terapia com células T CAR.
The primary objective of the report is to provide an overview of the market, including product scope, growth prospects, and potential risks. In-depth information about each participant in the global Terapia de células T CAR market, including that participant’s global standing, financial status, product launch, and business expansion plans, is included in the report. The participants in the market are concentrating their efforts on the creation of a variety of strategies, including partnerships, mergers and acquisitions, joint ventures, product launches, and investments in research and development.
According to the findings of the study, there are certain types of dangers and difficulties that can serve as an obstacle for a company. Granularity can be added to the overall research by performing an in-depth analysis of the Terapia de células T CAR market in the context of various aspects of the larger environment, such as the social, political, economic, and technological settings. In addition, the study generates real-time data on essential aspects such as sales, profits, gross margin, and growth prospects to demonstrate how going forward the company will see a significant upswing in its performance.
Outras descobertas significativas do relatório indicam que
In 2021, the segment of diffuse large B-cell linfoma was responsible for the majority of the rapid revenue share. A cancer of the lymphatic system, which is an essential component of the immune system, called diffuse large B-cell lymphoma has a rapid growth rate. It has an effect on the blood cells that generate antibodies, which are used to fight infections. In certain instances, DLBCL can be cured. The majority of patients suffering from DLBCL have a favourable response to initial treatments such as chemotherapy. In the case of some people, the illness either becomes resistant to treatment, which means that it no longer responds to it, or it relapses, which means that it returns after treatment has been completed. These patients may be candidates for treatment with terapia com células T receptoras de antígeno quimérico, which utilises the patient’s own immune cells in the fight against DLBCL. T-cells are taken out of the patient’s blood, modified in the laboratory with so-called chimeric antigen receptors that help in recognising and destroying cancer cells, and then reintroduced into the patient’s blood again. This process is repeated several times.
In 2021, the hospital segment was responsible for a fair amount of the total revenue. The CAR T-cell therapy will reprogramme the patient’s T-cells so that they will target the antigens produced by the tumour. CAR T-cell therapy has shown full remission rates of 80 to 90 percent in younger patients with B-cell acute lymphoblastic leukaemia, and it has shown a full remission rate of 40 percent in patients with symptomatic B-cell Linfomas não Hodgkin who have failed several prior lines of therapy. Both of these patient populations have B-cell acute lymphoblastic leukaemia.
As principais empresas que operam atualmente no mercado são investigadas mais detalhadamente neste relatório, assim como seus perfis de empresas, portfólios de produtos, estratégias de expansão e alianças estratégicas. Alguns exemplos desses tipos de alianças incluem fusões e aquisições, colaborações e joint ventures. Além disso, fornece destaques sobre as realizações e a situação financeira da empresa, bem como insights sobre o alcance de mercado e a posição global da empresa.
Empresas com perfil no mercado global Terapia T-Cell CAR:
Novartis AG, Pfizer Inc., CARsgen Therapeutics Co., Ltd, Daiichi Sankyo Company, Limited, Bristol-Myers Squibb Company, Astellas Pharma Inc., BioNTech SE, Biocad, F. Hoffmann-La Roche Ltd., e Eli Lilly and Company .
Leia mais sobre o relatório global do mercado CAR T-Cell Therapy em: https://www.emergenresearch.com/industry-report/car-t-cell-therapy-market
